Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)
- 1 February 2019
- journal article
- editorial
- Published by Elsevier in Annals of Oncology
- Vol. 30 (2) , 161-165
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Combination Therapy of Radiotherapy and Anti-PD-1/PD-L1 Treatment in Non–Small-cell Lung Cancer: A Mini-reviewClinical Lung Cancer, 2018
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung CancerNew England Journal of Medicine, 2017
- ESMO-Magnitude of Clinical Benefit Scale version 1.1Annals of Oncology, 2017
- PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosisEuropean Journal of Cancer, 2016
- Radiotherapy combination opportunities leveraging immunity for the next oncology practiceCA: A Cancer Journal for Clinicians, 2016
- Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancerScientific Reports, 2016
- A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)Annals of Oncology, 2015
- Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 studyThe Lancet Oncology, 2015
- The Challenge of Subgroup Analyses — Reporting without DistortingNew England Journal of Medicine, 2006
- The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and ElaborationAnnals of Internal Medicine, 2001